Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exelixis (DE:EX9)
BERLIN:EX9
Exelixis (EX9) Stock Price & Analysis
0 Followers
EX9 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€16.34 - €21.92
Previous Close€21.92
Volume0.00
Average Volume (3M)N/A
Market Cap
€6.41B
Enterprise Value€5.78B
Total Cash (Recent Filing)$995.30M
Total Debt (Recent Filing)$189.94M
Price to Earnings (P/E)N/A
Beta>-0.01
Next Earnings
Apr 30, 2024EPS Estimate
€0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding303,194,259
10 Day Avg. Volume16
30 Day Avg. VolumeN/A
Standard Deviation0.23
R-Squared0.04
Alpha0.12
Financial Highlights & Ratios
Price to Book (P/B)3.24
Price to Sales (P/S)10.15
Price to Cash Flow (P/CF)168.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.16
Enterprise Value/Gross Profit3.29
Enterprise Value/Ebitda20.39
Forecast
1Y Price Target
€24.73Price Target Upside12.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
Exelixis News
PremiumCompany Announcements
Jacqueline Wright to Exit Exelixis Board in 2024
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPromising clinical trial results indicate that the combination treatment of cabozantinib and atezolizumab could lead to substantial survival benefits, potentially driving the stock's upward momentum.
Intellectual Property ResolutionResolution of the intellectual property issue could significantly raise the stock's value and enhance its attractiveness as a merger and acquisition target.
Product Sales And DemandCabozantinib's consistent sales performance, matching expectations, suggests a strong demand and sets a positive outlook for future revenue growth.
Bears Say
Financial PerformanceThe reported treatment exposure duration for Cabometyx was revised to about 4 months, which was below the prior expectation of 7 months.
Legal And Regulatory ConcernsMSN has not received tentative approval from the FDA for its generic drug.
Market SentimentMost long-only investors are hesitant to own patent stocks, which adds to the challenges facing EXEL.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
2.59% Other Institutional Investors
97.41% Public Companies and
Individual Investors
EX9 FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was €16.34 and its highest was €21.92 in the past 12 months.
What is Exelixis’s market cap?
Currently, no data Available
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Apr 30, 2024 which is tomorrow.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Feb 06, 2024. The company reported €0.252 earnings per share for the quarter, beating the consensus estimate of €0.215 by €0.037.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is €0.21.
How many shares outstanding does Exelixis have?
Currently, no data Available
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of €0.252 in its last earnings report, beating expectations of €0.215. Following the earnings report the stock price went up 1.546%.
Which hedge fund is a major shareholder of Exelixis?
Among the largest hedge funds holding Exelixis’s share is Farallon Capital Management, L.L.C.. It holds Exelixis’s shares valued at 639M.
---
Exelixis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€24.73 (12.83% Upside)
€24.73 (12.83% Upside)
Blogger Sentiment
Bullish
DE:EX9 Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.45%
12-Months-Change
Fundamentals
Return on Equity
8.74%
Trailing 12-Months
Asset Growth
-2.44%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
---
EX9 Company Deck
---
EX9 Earnings Call
Q4 2024
0:00 / 0:00
---
EX9 Stock 12 Months Forecast
Average Price Target
€24.73
▲(12.83% Upside)
Technical Analysis
Best Analysts Covering EX9
1 Year
1 Year Success Rate
18/21 ratings generated profit
1 Year Average Return
+103.65%
reiterated a buy rating 7 months ago
Copying Michael Schmidt's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +103.65% per trade.
---